NicOx SA

278 articles about NicOx SA

• Nicox Provides Second Quarter 2022 Financial and Business Highlights

  7/20/2022

  Nicox SA, an international ophthalmology company, provided financial and business highlights for second quarter 2022 for Nicox SA and its subsidiaries and updated on key upcoming milestones.

• Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

  7/7/2022

  Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 -induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.

• Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

  6/3/2022

  Nicox SA, an international ophthalmology company, announced that it has closed screening for additional patients in its Phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension.

• Nicox Announces a New Governance Structure

  5/16/2022

  Nicox SA announced that its Board of Directors appointed Andreas Segerros as Chief Executive Officer of Nicox S.A on May 13th, 2022, effective from June 1st, 2022, following the Board’s decision to end the mandate of Michele Garufi, who has been Chairman, Chief Executive Officer and Co-Founder of the Company since its creation in 1996.

• Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470

  5/2/2022

  Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new non-clinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting, one of the key scientific events in vision research, being held in person on May 1-4, 2022 in Denver, CO, United States and virtually on May 11-12.

• Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones

  4/28/2022

  Sophia Antipolis announced the financial and operating results for Nicox and its subsidiaries for the year ended December 31, 2021, as approved by the Board of Directors on April 27, 2022, along with a business update and financial highlights for the first quarter 2022, and provided an update on key upcoming milestones.

• Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

  4/11/2022

  Nicox SA, an international ophthalmology company, announced that the results from its Dolomites Phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma, the official journal of the World Glaucoma Association.

• Nicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease

  3/2/2022

  Nicox SA, an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced that the United States Food and Drug Administration has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans.

• Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

  3/1/2022

  Nicox SA, an international ophthalmology company, announced positive results in a Chinese Phase 3 clinical trial of ZERVIATE®, 0.24%, run by its Chinese partner, Ocumension Therapeutics.

• Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries

  2/23/2022

  Nicox SA, an international ophthalmology company, provides an update on the approvals and launches of VYZULTA, 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc.

• Nicox Granted New Patent for NCX 4251 in Japan

  2/22/2022

  Nicox SA, an international ophthalmology company, announced that the Japanese Patent Office has granted a new patent expiring in 2040 covering the Company’s product candidate NCX 4251.

• Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039

  2/21/2022

  Nicox SA, an international ophthalmology company, announced that the Chinese National Intellectual Property Administration has granted the company a formulation patent for NCX 470, its lead product candidate in development for patients with open-angle glaucoma or ocular hypertension, extending coverage in China to 2039.

• Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye

  2/8/2022

  Nicox SA, an international ophthalmology company, announced that it will be focusing the future development of NCX 4251 on dry eye disease.

• Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2022

  1/27/2022

  Nicox SA announced that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months: Financial and pharmaceutical Industry conferences.

• Nicox Provides Fourth Quarter 2021 Business and Financial Highlights

  1/21/2022

  Nicox SA, an international ophthalmology company, provided business and financial highlights for fourth quarter 2021 for Nicox SA and its subsidiaries as well as key expected value-inflection milestones.

• 

  BioSpace Movers & Shakers, Dec. 17

  12/17/2021

  As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers.

• Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma

  12/16/2021

  Nicox SA, an international ophthalmology company, announced that the first patient has been screened in China in the ongoing Denali Phase 3 clinical trial, opening the way for New Drug Application submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma.

• Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development

  12/13/2021

  Nicox SA, an international ophthalmology company, announced the appointment of Doug Hubatsch to lead all of the Company’s non-clinical and clinical development activities.

• Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe

  11/17/2021

  Nicox SA, an international ophthalmology company, announced that patent EP 3,769,753, expiring in 2040 and covering the Company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office.

• Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting

  11/10/2021

  Nicox SA, an international ophthalmology company, announced a poster presentation highlighting responder analyses results from the Dolomites Phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021Annual Meeting being held from November 12-15, 2021 in New Orleans, LA, U.S.